Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GLO1 | Q04760 | 2/20 | 0.56 |
| ▸ | MAPT | P10636 | 10/20 | 0.53 |
| ▸ | MEN1 | O00255 | 9/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 9/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.53 |
| ▸ | HSP90AA1 | P07900 | 2/20 | 0.53 |
| ▸ | HPGD | P15428 | 1/20 | 0.53 |
| ▸ | LMNA | P02545 | 3/20 | 0.52 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.52 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.52 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.52 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.52 |
| ▸ | S1PR4 | O95977 | 1/20 | 0.52 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.52 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.45 |
| ▸ | CRHBP | P24387 | 1/20 | 0.45 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.45 |
| ▸ | NPC1 | O15118 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6137229 | 1.00 | GLO1 (0.56) | GLO1MAPTMEN1KMT2AALDH1A1 | |
| SCHEMBL11816723 | 0.93 | MEN1 (0.61) | GLO1MAPTMEN1KMT2AALDH1A1 | |
| SCHEMBL4778481 | 0.84 | KMT2A (0.61) | GLO1MAPTMEN1KMT2AALDH1A1 | |
| SCHEMBL4778485 | 0.84 | KMT2A (0.61) | GLO1MAPTMEN1KMT2AALDH1A1 | |
| SCHEMBL28449048 | 0.84 | GAA (0.50) | MAPTALDH1A1KDM4EHPGDGAA | |
| SCHEMBL9297690 | 0.84 | KMT2A (0.61) | GLO1MAPTMEN1KMT2AALDH1A1 | |
| SCHEMBL10375324 | 0.83 | GLO1 (0.64) | GLO1MAPTMEN1KMT2AALDH1A1 | |
| SCHEMBL7756019 | 0.83 | ALDH1A1 (0.55) | GLO1MAPTALDH1A1KDM4EGAA | |
| SCHEMBL9516698 | 0.82 | SMN1; SMN2 (0.44) | MAPTMEN1KMT2AALDH1A1HPGD | |
| SCHEMBL15026370 | 0.82 | GLO1 (0.65) | GLO1MAPTMEN1KMT2AALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1372657-A4 | A METHOD OF TREATING PROLIFERATIVE DISEASES USING EG5 INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2005-11-09 | — | — | EP | disclosed |
| EP-1372657-A2 | A METHOD OF TREATING PROLIFERATIVE DISEASES USING EG5 INHIBITORS | Bristol-Myers Squibb Company (US) | 2004-01-02 | — | — | EP | disclosed |
| US-20020165240-A1 | Method of treating proliferative diseases using Eg5 inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2002-11-07 | — | — | US | disclosed |
| WO-2002078639-A2 | A METHOD OF TREATING PROLIFERATIVE DISEASES USING EG5 INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2002-10-10 | — | — | WO | disclosed |
| US-4621082-A | Pyridopyrimidines, pharmaceutical compositions and use | BAYER AKTIENGESELLSCHAFT (DE) | 1986-11-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020165240-A1 | Method of treating proliferative diseases using Eg5 inhibitors | ARF5, PDS5A, GEMIN5 | GLO1 668/4885MAPT 2283/4885MEN1 509/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.